xRead - Olfactory Disorders (September 2023)

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

533

PATEL et al.

TABLE VIII.11 Section evidence summary: Use of validated survey QOL testing Study Year LOE Study design Study groups

Clinical end point

Conclusions

QOD-NS UPSIT R

Soler

2016 3

Prospective cohort

121 patients with CRSwho underwent ESS

Olfactory QOL worse with polyps and asthma Baseline QOD-NS and

et al 1250

UPSIT R scoreshad moderate correlation

Mattos

2017

3

Prospective cohort

109 patients with CRS

QOD-NS SS-TDI Correlations between

QOD-NS correlates with TDI, SNOT-22 QOD-NS can screen for OD based on receiver operating characteristic analysis Medical treatment of CRS was associated with short-term improvements in olfactory QOL, without improvement in OF OF did not associate with QOL measures Negligible associations were identified between OD and QOL among multiple nonolfactory QOL metrics in a community (non-CRS) population OD and polyp status were associated with improvement in all QOL measures after ESS Impaired olfactory QOL is associated with worse economic and productivity measures and greater medication use Self-reported smell loss had good discriminative ability to identify abnormal B-SIT scores Moderate associations were found between VAS and B-SIT scores ( r = 0.59) OD and gustatory dysfunction may be signs of early COVID-19 infection and these symptoms may serve as screening tools

et al 1251

olfactory metrics and patient/disease factors

Thomas

Endoscopy scores SS-TDI

2020 3

Prospective cohort

48 patients with CRS treated

et al 1252

QOD-NS SNOT-22

medically, short-term follow-up

Hinz

2019 3

Cross-sectional,

7267 individuals

SS-ID (12 odors) SF-8 GAD-7 scale LOT-R SWLS

et al 1253

community-based

not screened for CRS

Katotomi

SS-TDI QOD BDI SF-36

2014 3

Prospective cohort with control arm

111 patients with CRSwho underwent ESS 48 healthy patients 221 patients with CRS

chelakis et al 1256

Schlosser et al 1257

2017

3

Prospective cohort

UPSIT R QOD-NS Associations between olfactory measures and health care use, productivity, and medication use Olfaction scores via VAS B-SIT

Prajapati et al 1258

2020 3

Prospective cohort study

81 patients with

COVID-19, 54 of whom reported smell loss

Qui

2020 4

Multicenter case series

394 patients with COVID-19, 60 completed QOD

QOD VAS for olfactory/gustatory dysfunction

et al 1259

(Continues)